98%
921
2 minutes
20
Background: Uveitis is an infrequent disease which constitutes a major cause of ocular morbidity. Correct management is essential, being corticosteroids its cornerstone. In case of contraindication to corticosteroids or treatment failure, the use of topical tacrolimus (TAC) could be an alternative which has already demonstrated safety and effectiveness in other ocular pathologies. However, TAC eye drops are not marketed, thus their elaboration must be carried out in Hospital Pharmacy Departments (HPDs).
Methods: 32 Sprague-Dawley rats were divided into 4 groups of 8 rats each: (a) untreated healthy rats (Healthy); (b) untreated Endotoxin-Induced Uveitis model-rats (EIU); (c) EIU-rats treated with standard treatment of dexamethasone ophthalmic drops (DXM) and (d) EIU-rats treated with TAC-hydroxypropyl-β-cyclodextrin eye drops previously developed by our group (TAC-HPβCD). The mRNA expression levels of IL-6, IL-8, MIP-1α and TNF-α, quantitative analysis of leucocytes in aqueous humor and histological evaluation were performed.
Results: TAC-HPβCD eye drops demonstrated to reduce ocular inflammation, expression of IL-6, TNF-α, MIP-1α and leukocyte infiltration in aqueous humor.
Conclusions: TAC-HPβCD eye drops showed beneficial effect in EIU model in rats, positioning as an alternative for uveitis treatment in case of corticosteroids resistance or intolerance.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540547 | PMC |
http://dx.doi.org/10.3390/pharmaceutics13101737 | DOI Listing |
Ophthalmol Glaucoma
September 2025
Department of Ophthalmology and Visual Sciences, University of Michigan W.K. Kellogg Eye Center, Ann Arbor, Michigan. Electronic address:
Purpose: To investigate hand function and eye drop instillation success in adults with and without glaucoma.
Design: Cross-sectional pilot study.
Subjects: Adults aged ≥ 65 years with glaucoma who use eye drops daily and adults aged 65+ without glaucoma who do not regularly use eye drops.
Zhonghua Yan Ke Za Zhi
September 2025
Aier Glaucoma Institute, Hunan Engineering Research Center for Glaucoma with Artificial Intelligence in Diagnosis and Application of New Materials, Changsha Aier Eye Hospital, Changsha 410015, China.
As the world's leading irreversible blinding eye disease, glaucoma is predominantly managed with pharmaceutical interventions in clinical practice. However, long-term use of traditional eye drops containing preservatives (e.g.
View Article and Find Full Text PDFAdv Ther
September 2025
Centre d'Ophtalmologie Visis, 66000, Perpignan, France.
Introduction: Glaucoma treatment predominantly involves the use of topical anti-glaucoma eye drops, with patient adherence influenced by individual preferences. This study aimed to assess these preferences and highlight the importance of personalized treatment approaches among ophthalmologists.
Methods: This French multicenter, cross-sectional study involved 21 ophthalmologists-members of the Board of Directors of the French Society of Glaucoma-from both public and private practices, who distributed a standardized questionnaire to their patients with glaucoma.
Vestn Oftalmol
September 2025
Azerbaijan Medical University, Baku, Azerbaijan.
Objective: This study evaluated changes in ocular parameters in patients with progressive myopia receiving 0.01% atropine.
Material And Methods: The study included 35 children (18 girls, 51.
Transl Vis Sci Technol
September 2025
Wilmer Eye Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Purpose: The purinergic receptor P2X4 is critical to transduction of ocular pain. The aim of this study was to investigate the therapeutic potential of the P2X4 receptor antagonist BAY-776 in alleviating chronic ocular pain.
Methods: Chronic ocular pain was induced in male rats (8-9 weeks old; n = 12 per group) via double lacrimal gland removal (DLGR).